GlobalRPh Renal Dosing Masterv6.6
Evidence addition

Methylene blue - PROVAYBLUE

Local RX List renal extractBase record retrieved 2026-09-08See the evidence for this drug2 sources available - open source summaries, references and comparisons

PROVAYBLUE / Methylene blue

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Cautions / source differences (2)

Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.

Choose a source to read (2)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

2 additional source qualifications - review before use
PROVAYBLUE: renal impairment limits the selected course to one dose

The selected renal pathway calls for a single infusion and consideration of alternatives when response is inadequate. It does not authorize the general repeat-dose pathway.

Before applying: Retain acquired-methemoglobinemia scope and serotonergic-drug warnings. Do not extrapolate to vasoplegia.

PROVAYBLUE: renal single-dose instruction limits general repeat dosing

For the selected impaired-renal band, persistent methemoglobinemia prompts alternative interventions rather than the usual repeat-dose pathway.

Before applying: Do not reapply the general repeat-dose rule without the renal qualification.

Also check: PROVAYBLUE: renal impairment limits the selected course to one dose; PROVAYBLUE: renal single-dose instruction limits general repeat dosing

Rxlist source

GlobalRPh RX List - PROVAYBLUE

Product / population
Methylene blue - PROVAYBLUE renal repeat-dose limit; selected renal passages, not a complete prescribing monograph.
Renal measure
eGFR, mL/min/1.73 m2; retain body-surface-area indexing.

RX mirror: this is not independent corroboration of its underlying label. Check dated-label and formulation limitations.

Renal dosing, restrictions and evidence limits

For moderate or severe impairment, eGFR 15-59 mL/min/1.73 m2, the recommended regimen is a single 1 mg/kg dose. Administration is intravenous over 5-30 minutes. If methemoglobin remains >30% or symptoms persist 1 hour later, consider alternative interventions rather than applying the general repeat-dose paragraph. This selected renal instruction does not establish treatment below eGFR 15 or dialysis dosing. Full product contraindications and interaction warnings still apply.

Source revision: Source revision date not established in selected retrieval. | Retrieved: 2026-09-09. Retrieval date is not the revision date.

Source: https://globalrph.com/rx-list/provayblue-drug/

Scope: Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph. GlobalRPh v6.6.

Full source card / provenance

All sources, comparison tools and evidence navigation
Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Read 2 source difference / applicability notes

GlobalRPh RX List

GlobalRPh RX List - PROVAYBLUE

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Methylene blue - PROVAYBLUE; selected renal source sections only, not a complete prescribing monograph.

Renal method: eGFR, mL/min/1.73 m2. Preserve the body-surface-area denominator.
Retrieved: 2026-09-08

Read local renal resultOpen original reference
GlobalRPh RX List

GlobalRPh RX List - PROVAYBLUE

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Methylene blue - PROVAYBLUE renal repeat-dose limit; selected renal passages, not a complete prescribing monograph.

Renal method: eGFR, mL/min/1.73 m2; retain body-surface-area indexing.
Retrieved: 2026-09-09

Read local renal resultOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Product / population check

Confirm the exact formulation before using a renal source

These links compare product identities, not interchangeable doses. A selected summary is not a complete prescribing monograph.

Source-specific review points

PROVAYBLUE: renal impairment limits the selected course to one dosePROVAYBLUE: renal single-dose instruction limits general repeat dosing

Read the attributed comparison notes and source cards below. No conflict has been silently adjudicated.

Source-quality holds
Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. Searches stay on this page and are not saved or sent.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceRead 2 difference / caution notesClinician guide

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Read before choosing a regimen

Source differences and product cautions

Search differences across all drugs

These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.

dose table scope

PROVAYBLUE: renal impairment limits the selected course to one dose

The selected renal pathway calls for a single infusion and consideration of alternatives when response is inadequate. It does not authorize the general repeat-dose pathway.

How to use this: Retain acquired-methemoglobinemia scope and serotonergic-drug warnings. Do not extrapolate to vasoplegia.

GlobalRPh RX List - PROVAYBLUE

Source-specific interpretation; independent clinician adjudication pending.

dose table scope

PROVAYBLUE: renal single-dose instruction limits general repeat dosing

For the selected impaired-renal band, persistent methemoglobinemia prompts alternative interventions rather than the usual repeat-dose pathway.

How to use this: Do not reapply the general repeat-dose rule without the renal qualification.

GlobalRPh RX List - PROVAYBLUE

Source-specific interpretation; independent clinician adjudication pending.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

New source summary - independent clinical review pending. Summaries of the identified label sections are included locally. Source import and numeric transcription checks are not independent two-reference validation. Do not treat this card as an approved institutional dosing protocol.

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scopeGlobalRPh RX List - PROVAYBLUEGlobalRPh RX List - PROVAYBLUE
Choose two source checkboxes below.
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
Locally stored source content

Exact product and population

Product identity selected for the separately displayed source protocols below. Reference: https://globalrph.com/rx-list/provayblue-drug/

Exact product and population

Methylene blue - PROVAYBLUE; selected renal source sections only, not a complete prescribing monograph.

RDM47-SCOPE-methylene-blue-provayblue · Source section: Selected source product scopeRenal section finder
Locally imported selected renal sections

GlobalRPh RX List renal information

Rxlist

GlobalRPh RX List - PROVAYBLUE

Open original reference

Open / share this exact local source

GlobalRPh-hosted RX List · Methylene blue - PROVAYBLUE; selected renal source sections only, not a complete prescribing monograph.

Renal method: eGFR, mL/min/1.73 m2. Preserve the body-surface-area denominator.
Source date: Source revision date not established in selected retrieval.
Retrieved: 2026-09-08

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

For acquired methemoglobinemia with eGFR 15-59 mL/min/1.73 m2, the renal-specific recommendation is a single 1 mg/kg IV dose, administered over 5-30 minutes. If methemoglobin remains >30% or symptoms persist one hour later, consider alternative interventions rather than automatically repeating the general-population dose. Mild impairment (60-89) needs no adjustment. The boxed serotonergic-interaction warning still applies; this is not guidance for off-label vasoplegia.

RDM47-rxlist-methylene-blue-provayblue-db8c0c4789-C1 · Source locator: Dosage and renal-specific recommendations, lines 31-42; renal population 185-187; boxed warning 17-20.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/provayblue-drug/
Retrieved
2026-09-08
Renal-function method
eGFR, mL/min/1.73 m2. Preserve the body-surface-area denominator.
Source date/version
Source revision date not established in selected retrieval.
Hash meaning
SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256
a1620e55b6da960cb1b36d6ea9b175040482234addbe7347d19b50f318bf44e2
Rxlist

GlobalRPh RX List - PROVAYBLUE

Open original reference

Open / share this exact local source

GlobalRPh-hosted RX List · Methylene blue - PROVAYBLUE renal repeat-dose limit; selected renal passages, not a complete prescribing monograph.

Renal method: eGFR, mL/min/1.73 m2; retain body-surface-area indexing.
Source date: Source revision date not established in selected retrieval.
Retrieved: 2026-09-09

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

For moderate or severe impairment, eGFR 15-59 mL/min/1.73 m2, the recommended regimen is a single 1 mg/kg dose. Administration is intravenous over 5-30 minutes. If methemoglobin remains >30% or symptoms persist 1 hour later, consider alternative interventions rather than applying the general repeat-dose paragraph. This selected renal instruction does not establish treatment below eGFR 15 or dialysis dosing. Full product contraindications and interaction warnings still apply.

RDM50-rxlist-methylene-blue-provayblue-db8c0c4789-C1 · Source locator: Administration and renal-specific dosage, lines 33-42.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/provayblue-drug/
Retrieved
2026-09-09
Renal-function method
eGFR, mL/min/1.73 m2; retain body-surface-area indexing.
Source date/version
Source revision date not established in selected retrieval.
Hash meaning
SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256
60e89e848b10176694ec90c440b1578751289a99c6077f0f503f06062c24c489

Provenance and preservation

Additional summaries stored on this page: 0 official-label, 2 RX List, 0 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://globalrph.com/rx-list/provayblue-drug/
Source retrieval
2026-09-08. This is not the source publication or label revision date.
Original source type
rxlist summary
Local text SHA-256
5578c2478a07403d7cd6ccddebd19b89531a489d7271139c62ccda392d434f19
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.

Read the full coverage report